FasterCapital is excited to announce the acceptance of a groundbreaking Biotechnology project into its program. Led by the visionary Founder & CEO, Nouf Al Azizi, this startup aims to revolutionize the pharmaceutical industry by establishing a specialized facility for pharmaceutical manufacturing and medical laboratories in Saudi Arabia. The startup is raising $800K with the help of FasterCapital’s team.

What sets this startup apart is its focus on utilizing cutting-edge genetic engineering techniques within living cells to develop advanced biological medications that target complex diseases such as cancer, arthritis, multiple sclerosis, and autoimmune diseases. By leveraging these innovative techniques, the startup aims to provide more precise treatment options with enhanced recovery rates and reduced side effects compared to conventional drugs.

Hesham Zreik, CEO of FasterCapital, expressed his enthusiasm for this collaboration, stating, "We are thrilled to welcome such a forward-thinking startup into our program. The potential impact of their biopharmaceutical project on healthcare in Saudi Arabia and beyond is truly remarkable, and we are committed to supporting their journey towards success."

In response to the collaboration with FasterCapital, Founder & CEO Nouf Al Azizi expressed her gratitude, stating, "We are honored to join forces with FasterCapital and leverage their expertise in reviewing and raising capital for startups. This partnership will undoubtedly accelerate our progress towards establishing a thriving biopharmaceutical industry in Saudi Arabia and making a meaningful impact on healthcare outcomes."

Through FasterCapital's LaunchUp program, this biopharmaceutical startup will benefit from comprehensive support in refining their business model, accessing a global network of investors, and navigating the complexities of raising capital. Together, FasterCapital and the startup aim to drive innovation in the pharmaceutical industry.